Research Paper Volume 15, Issue 12 pp 5569—5591

Expression, prognostic value and mechanism of SP100 family in pancreatic adenocarcinoma

Yunjie Duan1, *, , Yongxing Du1, *, , Yongrun Mu1, , Zongting Gu2, , Chengfeng Wang1,3, ,

  • 1 State Key Lab of Molecular Oncology and Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
  • 2 Department of Hepatobiliary and Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China
  • 3 Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, China
* Equal contribution

Received: December 14, 2022       Accepted: May 23, 2023       Published: June 22, 2023
How to Cite

Copyright: © 2023 Duan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Background: Pancreatic adenocarcinoma (PAAD) is one of the most aggressive malignancies with a very poor prognosis. Exploring more therapeutic targets and prognostic biomarkers is of great significance to improve the prognosis of PAAD patients. Increasing evidence supports that the speckled protein (SP) 100 family is associated with human cancer and immune disorders. However, the function of the SP100 family members in PAAD is still unclear.

Methods: R, Cytoscape, cBioPortal, and other software and online databases were used to comprehensively analyze the expression characteristics, prognostic value, and oncogenic mechanism of the SP100 family in PAAD.

Results: The high expression of SP100 family members in PAAD was significantly correlated with poor clinicopathological features and poor prognosis of PAAD patients. Mechanistically, TP53 mutations were significantly associated with the expression levels of the SP100 family members, which were significantly coexpressed with M6A methylation regulators and were activated in multiple oncogenic pathways, including the EMT pathways. Moreover, we found that their expression levels were significantly correlated with the sensitivity of multiple traditional chemotherapeutic drugs.

Conclusion: The SP100 family is closely related to the occurrence and development of PAAD and can be used as a new biomarker and therapeutic target for patients with PAAD.


PAAD: pancreatic adenocarcinoma; SP: speckled protein; TCGA: The Cancer Genome Atlas; GTEx: Genotype-Tissue Expression; OS: overall survival; RFS: recurrence-free survival; GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; BP: biological process; CC: cellular components; MF: molecular function; PPI: protein–protein interaction; CHOL: cholangio carcinoma; STAD: stomach adenocarcinoma; LUAD: lung adenocarcinoma; OV: ovarian serous cystadenocarcinoma; UCEC: uterine corpus endometrial carcinoma; EMT: epithelial–mesenchymal transition; ROC: receiver operating characteristic; AUC: The area under the curve.